NOSH-aspirin

NOSH-Aspirin is a category of new hybrids of acetylsalicylic acid, bearing both nitric oxide (NO)- and hydrogen sulfide (H2S)- releasing areas.

Preliminary studies have found that four NOSH variants, evaluated in eleven different human cancer cell lines, were effective in inhibiting the growth of these cell lines.

NOSH-1 was also devoid of any cellular toxicity, and was comparable to aspirin in its anti-inflammatory properties.

[1][2] This oncology article is a stub.

You can help Wikipedia by expanding it.

Chemical structure of NOSH-Aspirin, with highlighted acetylsalicylic acid (green), sulfide-releasing (yellow), and nitric oxide-releasing (blue) groups.